(2011). IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients. Oncotarget, 2(3), 178-185. Each mature T cell or B cell has an allele with a productively rearranged T cell receptor (TCR) or B cell receptor (BCR) gene, respectively. The repertoire of TCRs and BCRs in the blood of a healthy person is diverse, with no single specific rearrangement found in more than one pe...

Mediastinal masses in children comprise a heterogeneous group of malignant and benign neoplasms. The majority of malignant tumors of mediastinum are Hodgkins and non-Hodgkins lymphomas, germ cell tumors, and neuroblastomas. Thymic tumors account for 1.5% of mediastinal masses in children [1]. Thymomas, thymic carcinoids, and thymic carcinomas constitute thymic epithelial neoplasms (TEN). Carcin...

Over the past decade, novel pathogens causing infections in patients have been identified. Chryseobacterium is one such emerging pathogen that frequently reported hospitalized patients. Case reports of bloodstream infections, and pneumonia due to spp cancer from different parts world are drawing attention clinical community this bacterium as an threat with malignancies. Besides its propensity c...

original article   evaluation of lymphadenopathy is of clinical significance as the underlying disease may range from a treatable infectious etiology to malignant neoplasm. the aim and objective of the present study was to evaluate palpable lymph nodes of population working in small to medium scale industries represented as group a by fine needle aspiration cytology (fnac) and to compare the re...

Acute leukemia is reported to be less common in developing countries compared to non-Hodgkins lymphomas which is the most common childhood malignancy. A retrospective analysis was performed to identify the clinicopathological features of acute leukemias of childhood at the Oncology Department of Allama Iqbal Medical College, Lahore. The commonest malignancy in the under 15 years age group was l...

Targeted alpha therapy (TAT) is an emerging option for local and systemic cancer treatment. Preclinical research and clinical trials show that alpha-emitting radionuclides can kill targeted cancer cells while sparing normal cells, thus reducing toxicity. (223)RaCl2 (Xofigo(®)) is the first alpha emitting radioisotope to gain registration in the US for palliative therapy of prostate cancer bone ...